is hereby given of the following meeting of the National Cancer Institute Initial Review Group:

   Agenda/Purpose: To review, discuss and evaluate individual grant applications.
   Committee Name: Subcommittee G—Clinical Trials.
   Date: March 24–25, 1998.
   Time: March 24—8:00 a.m. to Recess; March 25—8:00 a.m. to Adjournment.
   Place: Double Tree Hotel, 1750 Rockville Pike, Rockville, Maryland 20852.
   Contact Person: John L. Meyer, Ph.D., Scientific Review Administrator, 6130 Executive Blvd., EPN, Room 611C, Bethesda, MD 20892–7403, Telephone: 301–496–7721.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Centers Support; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

LaVerne Y. Stringfield,
Committee Management Officer, NIH.
[FR Doc. 98–3468 Filed 2–10–98; 8:45 am]
BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting of the National Cancer Institute Initial Review Group:

   Name of SEP: Long-term Cancer Survivors: Research Initiatives.
   Date: March 17–20, 1998.
   Time: March 17—7:00 p.m. to Recess; March 18 & 19—8:00 a.m. to Recess; March 20—8:00 a.m. to Adjournment.
   Place: Holiday Inn—Bethesda, 8120 Wisconsin Avenue, Bethesda, MD 20814.
   Contact Person: Wilna Woods, Ph.D., Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 622B, 6130 Executive Boulevard, Bethesda, MD 20892–7405, Telephone: 301/496–7903.
   Purpose/Agenda: To review, discuss and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

LaVerne Y. Stringfield,
Committee Management Officer, NIH.
[FR Doc. 98–3469 Filed 2–10–98; 8:45 am]
BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Heart, Lung, and Blood Institute Special Emphasis Panel (SEP) meetings:

Name of SEP: Cooley’s Anemia Review Meeting.

   Name of SEP: Psychosocial Factors and Cardiovascular Disease.
   Date: March 31, 1998.
   Time: 8:00 a.m.
   Place: Holiday Inn Bethesda, 8120 Wisconsin Avenue, Bethesda, Maryland 20814.
   Contact Person: C. James Scheirer, Ph.D., Two Rockledge Center, Room 7220, Bethesda, MD 20892–7924, (301) 435–0299.
   Purpose/Agenda: To review and evaluate grant applications.

These meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health)

LaVerne Y. Stringfield,
Committee Management Officer, NIH.
[FR Doc. 98–3477 Filed 2–10–98; 8:45 am]
BILLING CODE 4140–01–M